FDA Determines Regulatory Review Period for BIZENGRI Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for BIZENGRI, a human biological product, in accordance with federal regulations, following a submission to the U.S. Patent and Trademark Office (USPTO).